Earnings ·
Acumen Pharmaceuticals reports $110.2M cash balance, R&D costs drop to $27.8M in Q2 2026
ABOSAcumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2026, on August 12, 2026. The company held $110.2 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which is expected to fund operations into early 2027. Research and development expenses decreased to $27.8 million from $37.1 million in the prior year period due to lower manufacturing and clinical trial costs. The company expects to report topline results for its Phase 2 ALTITUDE-AD study of sabirnetug in late 2026 and targets an IND filing for its Enhanced Brain Delivery program lead candidate by mid-2027.